Preparation method of deer-horn glue micromolecular collagen and application of deer-horn glue micromolecular collagen in treatment of thyroid nodules

By preparing small-molecule collagen from deer antler glue, the problem of high risk and long treatment cycle in existing methods for treating thyroid nodules has been solved, providing a treatment option with low side effects and significantly improving thyroid function and tissue structure.

CN120866455APending Publication Date: 2025-10-31INST OF SPECIAL ANIMAL & PLANT SCI OF CAAS +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510953630.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-07-10
Publication Date
2025-10-31

AI Technical Summary

Technical Problem

Existing treatments for thyroid nodules have problems such as high surgical risks, the possibility of hypothyroidism caused by radioactive iodine therapy, and long treatment cycles with Western medicine, and there is a lack of effective therapies with low side effects.

Method used

A method for preparing deer antler gelatin small molecule collagen was adopted, including steps such as decoction, concentration, and enzymatic hydrolysis, to prepare deer antler gelatin small molecule collagen, which was then applied in a drug for treating thyroid nodules.

Benefits of technology

This provides a new treatment option for thyroid nodules with low side effects, significantly improving thyroid function and tissue structure, and reducing the risks associated with surgery and radiation therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120866455A_ABST
    Figure CN120866455A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of collagen, and particularly relates to a preparation method of deer-horn glue micromolecular collagen and application of the deer-horn glue micromolecular collagen in treating thyroid nodules. According to the preparation method of the deer-horn glue small-molecule collagen, the deer-horn glue small-molecule collagen is prepared from deer flower disc through specific steps of decoction, concentration, enzymolysis and the like, the deer-horn glue small-molecule collagen has an obvious effect on thyroid diseases, and a new scheme is provided for treatment of the thyroid diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application belongs to the field of collagen technology, specifically relating to the preparation of a small molecule collagen from deer antler glue and its application in the treatment of thyroid nodules. Background Technology

[0002] Thyroid nodules are a common thyroid disease in clinical practice, and their incidence is increasing year by year. The formation of thyroid nodules is related to multiple factors, including genetic factors, environmental factors, abnormal iodine intake, and autoimmune disorders. Most patients with thyroid nodules have no obvious clinical symptoms, but some nodules may cause thyroid dysfunction, or, due to their large size, cause compressive symptoms, such as difficulty breathing due to tracheal compression or difficulty swallowing due to esophageal compression, seriously affecting the patient's health and quality of life.

[0003] In terms of treatment, common methods include surgical resection, radioactive iodine therapy, and Western medicine. Surgical resection carries certain risks, such as postoperative bleeding, infection, damage to the recurrent laryngeal nerve leading to hoarseness, and hypoparathyroidism. Radioactive iodine therapy may cause adverse reactions such as hypothyroidism, and these treatments place a significant burden on patients both physically and psychologically. Western medicine treatments have long cycles, and patients are prone to missing doses or discontinuing medication on their own. Therefore, seeking treatments with low adverse reactions and outstanding therapeutic effects is the direction of medical research.

[0004] Small molecule collagen, due to its small molecular weight, has better solubility and bioactivity, making it easier for the human body to absorb and utilize, and has received more attention in the field of medical research. Deer antler glue is a solid glue made by boiling and concentrating the ossified antlers or detached flower discs of deer after velvet antlers are cut off. Modern pharmacological studies have shown that deer antler glue has anti-inflammatory and analgesic effects, warms and tonifies the liver and kidneys, nourishes yang, benefits essence and blood, resists breast hyperplasia, and combats osteoporosis.

[0005] However, there are currently no reports on the preparation of small molecule collagen from deer antler glue or its application in thyroid diseases. Summary of the Invention

[0006] Based on this, one embodiment of this application provides a method for preparing deer antler gelatin small molecule collagen and its application in the treatment of thyroid nodules.

[0007] This application provides a method for preparing deer antler gelatin small molecule collagen, including:

[0008] The deer antler disc was mixed with a solvent and then boiled, and the filtrate was collected.

[0009] The filtrate was concentrated to a thick paste, solidified, and dried to prepare deer antler glue.

[0010] The deer antler glue was mixed with a protease to prepare a mixture, which was then incubated. The enzymatic supernatant was collected to prepare deer antler glue small molecule collagen.

[0011] The concentration of the protease is 20 mg / mL to 25 mg / mL.

[0012] In one embodiment, the preparation method includes the deer antler disc being in powder form.

[0013] In one embodiment, the solvent includes water.

[0014] In one embodiment, the protease includes proteinase K.

[0015] In one embodiment, the mass-to-volume ratio of the deer antler disc to the solvent is 1:(8-12).

[0016] In one embodiment, the decoction process includes repeatedly decocting the residue after decoction two to four times and combining the filtrates.

[0017] In one embodiment, the concentration process includes heating concentration; optionally, the heating temperature of the concentration process is 50°C-70°C.

[0018] In one embodiment, the coagulation drying includes natural condensation drying; alternatively, the natural condensation drying includes removing the item, cutting it into small pieces, and air-drying it.

[0019] In one embodiment, the concentration of the protease is 20 mg / mL to 25 mg / mL.

[0020] In one embodiment, the incubation conditions include: a temperature of 55°C-60°C, a pH of 7.5-8.5, and a time of 5h-3h.

[0021] In one embodiment, the method for collecting the enzymatic hydrolysis supernatant includes centrifugation; optionally, the centrifugation parameters include: a rotation speed of 9000 rpm to 10000 rpm and a time of 8 min to 15 min.

[0022] This application also provides the antler glue small molecule collagen prepared by the above-mentioned method.

[0023] This application also provides the use of the above-mentioned deer antler gelatin small molecule collagen in the preparation of drugs for treating thyroid diseases.

[0024] In one embodiment, the thyroid disease includes thyroid nodules.

[0025] In one embodiment, the subject of the drug is a primate.

[0026] In one embodiment, the subject of the drug is a human being.

[0027] This application also provides a medicament for treating thyroid diseases, the medicament composition comprising the above-mentioned deer antler gelatin small molecule collagen.

[0028] Optionally, the drug may also include pharmaceutically acceptable excipients.

[0029] In one embodiment, the dosage form of the drug includes one or more of tablets, capsules, granules, oral liquids, and injections.

[0030] This application provides a method for preparing deer antler gelatin small molecule collagen, which is obtained from deer antler disc through specific steps such as boiling, concentration, and enzymatic hydrolysis. It is effective for thyroid diseases and provides a new solution for the treatment of thyroid diseases. Attached Figure Description

[0031] To more clearly illustrate the technical solutions in the embodiments of this application and to more completely understand this application and its beneficial effects, the drawings used in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of this application. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0032] Figure 1 Figures showing the body weight, thyroid tissue, and thyroid coefficient of rats in each group;

[0033] Figure 2 The results of HE staining of thyroid tissue from rats in each group are shown in the figure.

[0034] Figure 3 The statistical results of TSH, FT3, and FT4 levels in the serum of rats in each group are presented.

[0035] Figure 4 The statistical results of VEGF content in the thyroid tissue of rats in each group are as follows;

[0036] Figure 5 Immunohistochemical images of Caspase3 and Bcl-2 protein expression in thyroid tissues of rats in each group. Detailed Implementation

[0037] The present application will be further described in detail below with reference to the embodiments and examples. It should be understood that these embodiments and examples are for illustrative purposes only and are not intended to limit the scope of the present application. The purpose of providing these embodiments and examples is to enable a more thorough and comprehensive understanding of the disclosure of the present application. It should also be understood that the present application can be implemented in many different forms and is not limited to the embodiments and examples described herein. Those skilled in the art can make various modifications or alterations without departing from the spirit of the present application, and the equivalent forms obtained also fall within the protection scope of the present application. Furthermore, numerous specific details are set forth in the following description to provide a fuller understanding of the present application. It should be understood that the present application can be implemented without one or more of these details.

[0038] Unless otherwise defined, all technical and scientific terms used in this application have the same meaning as commonly understood by one of ordinary skill in the art to which this application pertains.

[0039] the term

[0040] Unless otherwise stated or in case of contradiction, the terms or phrases used herein shall have the following meanings:

[0041] The terms "and / or," "or / and," and "and / or" as used herein include any one of two or more of the related listed items, as well as any and all combinations of the related listed items. These arbitrary and all combinations include any two related listed items, any more related listed items, or a combination of all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or," "or / and," and "and / or," it should be understood that in this application, the technical solution undoubtedly includes technical solutions connected by "logical AND," and also undoubtedly includes technical solutions connected by "logical OR." For example, "A and / or B" includes three parallel solutions: A, B, and A+B. For example, the technical solution of "A, and / or, B, and / or, C, and / or, D" includes any one of A, B, C, and D (that is, a technical solution that is connected by "logical OR"), as well as any and all combinations of A, B, C, and D, that is, combinations of any two or three of A, B, C, and D, and also combinations of all four of A, B, C, and D (that is, a technical solution that is connected by "logical AND").

[0042] In this application, the terms "multiple", "various", "multiple times", "multi-dimensional", etc., unless otherwise specified, refer to a quantity greater than or equal to 2. For example, "one or more" means one or more than or equal to two.

[0043] The terms “combinations of,” “any combination of,” and “any combination of” used in this article include all suitable combinations of any two or more of the listed items.

[0044] In this document, the term "suitable" as used in phrases such as "suitable combination," "suitable method," and "any suitable method" refers to the ability to implement the technical solution of this application, solve the technical problem of this application, and achieve the expected technical effect of this application.

[0045] In this application, terms such as "further," "even further," and "particularly" are used to describe purposes and indicate differences in content, but should not be construed as limiting the scope of protection of this application.

[0046] In this application, "optionally," "optionally," and "optional" mean that something is optional, that is, it means that it is selected from either "with" or "without." If there are multiple "optional" entries in a technical solution, unless otherwise specified, and there are no contradictions or mutual constraints, each "optional" entry shall be independent.

[0047] In this application, the technical features described in an open-ended manner include both closed technical solutions consisting of the listed features and open technical solutions that include the listed features.

[0048] In this application, numerical intervals (i.e., numerical ranges) are involved. Unless otherwise specified, the selected numerical distributions within the aforementioned numerical intervals are considered continuous and include the two endpoints (i.e., the minimum and maximum values) of the numerical range, as well as every value between these two endpoints. Unless otherwise specified, when a numerical interval refers only to integers within that interval, it includes the two endpoint integers of the numerical range, as well as every integer between the two endpoints. In this document, this is equivalent to directly listing every integer. For example, if t is an integer selected from 1 to 10, it means that t is any integer selected from the group of integers consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. Furthermore, when multiple ranges are provided to describe features or characteristics, these ranges can be merged. In other words, unless otherwise specified, the ranges disclosed herein should be understood to include any and all subranges to which they are included.

[0049] Unless otherwise specified, the temperature parameters in this application are permitted to be either constant-temperature treatment or variations within a certain temperature range. It should be understood that the constant-temperature treatment allows temperature fluctuations within the precision range of the instrument control, such as ±5℃, ±4℃, ±3℃, ±2℃, or ±1℃.

[0050] In this application, % (w / w) and wt% both represent weight percentage, % (v / v) refers to volume percentage, and % (w / v) refers to mass-volume percentage.

[0051] All references to documents mentioned in this application are incorporated herein by reference as if each document were individually incorporated herein by reference. Unless they conflict with the inventive purpose and / or technical solution of this application, all cited documents are incorporated herein by reference in their entirety and for all purposes. When citing documents in this application, the definitions of relevant technical features, terms, nouns, phrases, etc., are also incorporated herein by reference. When citing documents in this application, examples and preferred embodiments of the cited technical features may also be incorporated herein by reference, but only to the extent that they enable the implementation of this application. It should be understood that when the cited content conflicts with the description in this application, this application shall prevail or modifications shall be made adaptably to the description in this application.

[0052] This application provides a method for preparing deer antler gelatin small molecule collagen, including:

[0053] The deer antler disc was mixed with a solvent and then boiled, and the filtrate was collected.

[0054] The filtrate was concentrated to a thick paste, solidified, and dried to prepare deer antler glue.

[0055] The deer antler glue was mixed with a protease to prepare a mixture, which was then incubated. The enzymatic supernatant was collected to prepare deer antler glue small molecule collagen.

[0056] Among them, deer antler disc powder is in powder form. Deer antler disc powder usually refers to deer antler disc powder, which is the ossified antler disc left on the head of a sika deer or red deer after antler harvesting. It is then ground into powder and used for traditional Chinese medicine treatment.

[0057] In some of these embodiments, the solvent includes water.

[0058] In some of these embodiments, the protease includes proteinase K.

[0059] In some embodiments, the mass-to-volume ratio of deer antler powder to solvent is 1:(8-12). For example, the volume ratio is 1:8, 1:9, 1:10, 1:11, or 1:12.

[0060] In some embodiments, the decoction process includes repeatedly decocting the residue 2 to 4 times and combining the filtrates. For example, the number of decoctions may be 2, 3, or 4.

[0061] In some embodiments, the concentration process is carried out at temperatures between 50°C and 70°C. For example, concentration temperatures can be 50°C, 51°C, 52°C, 53°C, 54°C, 55°C, 56°C, 57°C, 58°C, 59°C, 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, or 70°C, or any value in between.

[0062] In some embodiments, condensation drying employs spray condensation drying or natural condensation drying.

[0063] In some embodiments, the concentration of the proteolytic enzyme is 20 μg / mL to 25 μg / mL. For example, the concentration of the proteolytic enzyme is 20 μg / mL, 21 μg / mL, 22 μg / mL, 23 μg / mL, 24 μg / mL, or 25 μg / mL, or any value in between.

[0064] In some embodiments, the enzymatic hydrolysis conditions include: a temperature of 55°C-60°C, a pH of 7.5-8.5, and a time of 1.5h-3h. For example, temperatures of 55°C, 56°C, 57°C, 58°C, 59°C, or 60°C, and any value in between; pH values ​​of 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, or 8.5, and any value in between; and time values ​​of 1.5h, 1.6h, 1.7h, 1.8h, 1.9h, 2.0h, 2.1h, 2.2h, 2.3h, 2.4h, 2.5h, 2.6h, 2.7h, 2.8h, 2.9h, or 3.0h, and any value in between.

[0065] In some embodiments, the centrifugation parameters include a rotation speed of 9000 rpm to 10000 rpm and a time of 8 min to 15 min. For example, rotation speeds of 9000 rpm, 9100 rpm, 9200 rpm, 9300 rpm, 9400 rpm, 9500 rpm, 9600 rpm, 9700 rpm, 9800 rpm, 9900 rpm, or 10000 rpm, and times of 8 min, 9 min, 10 min, 11 min, 12 min, 13 min, 14 min, or 15 min, or any value in between.

[0066] The present application provides a method for preparing deer antler gelatin small molecule collagen.

[0067] Another aspect of this application provides the application of deer antler gelatin small molecule collagen in the preparation of drugs for treating thyroid diseases.

[0068] In some of these embodiments, thyroid disease includes thyroid nodules.

[0069] Another aspect of this application provides a medicament for treating thyroid diseases, the medicament comprising the aforementioned deer antler gelatin small molecule collagen;

[0070] In some embodiments, the drug also includes pharmaceutically acceptable excipients.

[0071] In some embodiments, the dosage form of the drug includes one or more of tablets, capsules, granules, oral liquids, and injections.

[0072] In this application, "pharmaceuticalally acceptable excipient" means a pharmaceutically acceptable material, composition, or carrier, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material. As used herein, the phrase "pharmaceuticalally acceptable excipient" includes buffers compatible with drug administration, sterile water for injection, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents and absorption delay agents, and the like. Each carrier must be "pharmaceuticalally acceptable" in the sense of compatibility with other components in the formulation and harmlessness to the patient. Suitable examples include, but are not limited to: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch, potato starch and substituted or unsubstituted β-cyclodextrins; (3) cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth gum; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn... Rice oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerol, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffer; and (21) other non-toxic compatible substances used in pharmaceutical formulations.

[0073] In this application, "excipients" include, but are not limited to, mannitol, sorbitol, sodium metabisulfite, sodium bisulfite, sodium thiosulfate, cysteine ​​hydrochloride, thioglycolic acid, methionine, vitamin C, disodium EDTA, calcium sodium EDTA, carbonates, acetates, phosphates or aqueous solutions of monovalent alkali metals, hydrochloric acid, acetic acid, sulfuric acid, phosphoric acid, amino acids, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, fructooligosaccharides, dextran, glycine, starch, sucrose, dextrin (such as maltodextrin), lactose, mannitol, silicon derivatives, cellulose and its derivatives, alginate, gelatin, polyvinylpyrrolidone, glycerol, Tween 80, agar, calcium carbonate, calcium bicarbonate, surfactants, polyethylene glycol, cyclodextrin, phospholipids, kaolin, talc, calcium stearate, and magnesium stearate.

[0074] One or more embodiments of this application provide a method for treating thyroid diseases, including administering a therapeutically effective amount of deer antler gelatin small molecule collagen prepared by the preparation method of this application to a subject.

[0075] In some embodiments, the administration of the drug includes, but is not limited to: oral, rectal, parenteral (intravenous, intramuscular or subcutaneous) injection, local administration, and inhalation.

[0076] In some of these embodiments, the drug may be administered orally, via enema, or via parenteral administration.

[0077] In some embodiments, the drug administration cycle may be intermittent, periodic, continuous, or long-term.

[0078] Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active ingredient is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with: (a) fillers or compatibilizers, such as starch, lactose, sucrose, glucose, mannitol, and silica; (b) binders, such as hydroxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, and gum arabic; (c) humectants, such as glycerin; (d) disintegrants, such as agar, calcium carbonate, potato starch or cassava starch, alginate, certain complex silicates, and sodium carbonate; (e) slowing agents, such as paraffin; (f) absorption accelerators, such as quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glyceryl monostearate; (h) adsorbents, such as kaolin; and (i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium dodecyl sulfate, or mixtures thereof. Buffers may also be included in capsules, tablets, and pills.

[0079] Solid dosage forms such as tablets, sugar pills, capsules, pellets, and granules can be prepared using coatings and shells, such as casings and other materials known in the art. They may contain opacifying agents, and the release of the active ingredient in such compositions can be delayed in a portion of the digestive tract. Examples of encapsulating components that can be used are polymeric substances and waxes. If necessary, the active ingredient may also be formed into microcapsules with one or more of the excipients described above.

[0080] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, or tinctures. In addition to the active ingredient, liquid dosage forms may contain inert diluents conventionally used in the art, such as water or other solvents, solubilizers, and emulsifiers, specifically, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide, and oils, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil, and sesame oil, or mixtures thereof. Besides these inert diluents, the composition may also contain adjuvants such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents, and fragrances. For example, suspensions may contain suspending agents, specifically, for example, ethoxylated isooctadecyl alcohol, polyoxyethylene sorbitol and dehydrated sorbitan esters, microcrystalline cellulose, aluminum methoxide, and agar, or mixtures thereof.

[0081] Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions, or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous or non-aqueous carriers, diluents, solvents, or excipients include water, ethanol, polyols, and suitable mixtures thereof.

[0082] Dosage forms for topical administration include ointments, powders, patches, sprays, and inhalers. They are prepared by mixing the active ingredient under sterile conditions with pharmaceutically acceptable excipients and any preservatives, buffers, or propellants as needed.

[0083] It is understood that the drugs in the embodiments of this application can be prepared into suitable clinical dosage forms by adding different pharmaceutically acceptable carriers, including but not limited to the dosage forms described above.

[0084] In this application, "subject" refers to an animal, preferably a mammal, and more preferably a human. Subjects include, but are not limited to, consumers of health products and patients with diseases, conditions, and / or symptoms. The subject in this invention is preferably a mammal. The term "mammal" primarily refers to warm-blooded vertebrate mammals, including but not limited to: cats, dogs, rabbits, bears, foxes, wolves, monkeys, deer, mice (such as rats and mice), pigs, cattle, sheep, horses, and humans, preferably primates, and more preferably humans.

[0085] In some embodiments, the drug is applicable to humans or other mammals. In this invention, "other mammals" does not refer to humans, and non-limiting examples of "other mammals" include cats, dogs, rabbits, bears, foxes, wolves, monkeys, deer, mice (such as rats and mice), pigs, cattle, sheep, horses, etc., and further include mice or rats; non-limiting examples of "other mammals" also include primates.

[0086] In some of these embodiments, the subjects of the drug are primates.

[0087] In some of these embodiments, the subject of the drug is a human being.

[0088] The embodiments of this application will be described in detail below with reference to examples. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of this application. For experimental methods in the following embodiments where specific conditions are not specified, please refer to the guidelines given in this application, or follow experimental manuals or conventional conditions in the art, or follow the conditions recommended by the manufacturer, or refer to experimental methods known in the art.

[0089] In the specific embodiments described below, the measurement parameters involving raw material components may have slight deviations within the weighing accuracy range unless otherwise specified. Temperature and time parameters are subject to acceptable deviations due to instrument testing accuracy or operational precision.

[0090] It should be understood that in the various embodiments of this application, the order of the above-mentioned processes does not imply the order of execution. The execution order of each process should be determined by its function and internal logic, and should not constitute any limitation on the implementation process of the embodiments of this application.

[0091] Example 1: Extraction of small molecule collagen from deer antler glue

[0092] Weigh 300g of deer antler powder and place it in a clay pot. Add 3L of distilled water, heat to boiling, and maintain a gentle boil for 1 hour. Filter, and repeatedly boil the residue three times. Combine the filtrates and concentrate over low heat to a thick paste. Pour into a gelation tank and allow to cool naturally. Remove, cut into small pieces, and air-dry to obtain 99.43g of deer antler glue. Weigh 16.9g of deer antler glue, add 422.5mL of distilled water (40mg / mL), add 20mg / mL proteinase K, incubate at 58℃ and pH 8.0 for 2 hours, centrifuge at 9500rpm for 10 minutes, collect the supernatant, and freeze-dry. Yield: 9.7g, yield: 57.4%, as shown in Table 1.

[0093] Example 2: Extraction of small molecule collagen from deer antler glue

[0094] Weigh 300g of deer antler powder and place it in a clay pot. Add 3L of distilled water, heat to boiling, and maintain a gentle boil for 1 hour. Filter, and repeatedly boil the residue three times. Combine the filtrates and concentrate over low heat until a thick paste forms. Pour into a gelation tank and allow to cool naturally. Remove, cut into small pieces, and air-dry to obtain 99.43g of deer antler glue. Weigh 16.9g of deer antler glue, add 422.5mL of distilled water (40mg / mL), add 25mg / mL proteinase K, incubate at 58℃ and pH 8.0 for 2 hours, centrifuge at 9500rpm for 10 minutes, collect the supernatant, and freeze-dry. Yield: 8.6g, 50.9% yield.

[0095] The extraction of small molecule collagen from deer antler glue in Comparative Example 1 was basically the same as in Example 1, except that the concentration of proteinase K was 15 mg / mL.

[0096] Weigh 300g of deer antler gelatin powder and place it in a clay pot. Add 3L of distilled water, heat to boiling, and maintain a gentle boil for 1 hour. Filter, and repeatedly boil the residue three times. Combine the filtrates and concentrate over low heat until a thick paste forms. Pour into a gelation tank and allow to cool naturally. Remove, cut into small pieces, and air-dry to obtain 99.43g of deer antler gelatin. Weigh 16.9g of deer antler gelatin, add 422.5mL of distilled water (40mg / mL), add 15mg / mL proteinase K, incubate at 58℃ and pH 8.0 for 2 hours, centrifuge at 9500rpm for 10 minutes, collect the supernatant, and freeze-dry. Yield: 6.6g, 39.1% yield.

[0097] The extraction of small molecule collagen from deer antler glue in Comparative Example 2 was basically the same as in Example 1, except that the concentration of proteinase K was 10 mg / mL.

[0098] Weigh 300g of deer antler powder and place it in a clay pot. Add 3L of distilled water, heat to boiling, and maintain a gentle boil for 1 hour. Filter, and repeatedly boil the residue three times. Combine the filtrates and concentrate over low heat to a thick paste. Pour into a gelation tank and allow to cool naturally. Remove, cut into small pieces, and air-dry to obtain 99.43g of deer antler glue. Weigh 16.9g of deer antler glue, add 422.5mL of distilled water (40mg / mL), add 10mg / mL proteinase K, incubate at 58℃ and pH 8.0 for 2 hours, centrifuge at 9500rpm for 10 minutes, collect the supernatant, and freeze-dry. Yield: 4.7g, 27.8% yield.

[0099] Table 1

[0100]

[0101] Example 3: Study on the therapeutic effect of the deer antler gelatin small molecule collagen prepared in Example 1 of this application on a rat model of thyroid nodules.

[0102] 1. Materials and Methods

[0103] 1.1 Experimental Animals: Thirty-four healthy male SPF-grade SD rats, weighing (200±20) g, were provided by Shenyang Changsheng Biotechnology Co., Ltd., and randomly divided into 9 cages with 4 rats per cage. The rearing temperature was (25±1)℃ and the humidity was (55±10)%. The rats had free access to water and food and were acclimatized for 7 days.

[0104] 1.2 Drugs and Reagents: Propylthiouracil (PTU): Beijing Solarbio. Levothyroxine Sodium Tablets (Urothyroxine): Merck, Germany. Free Triiodothyronine (FT3) ELISA Kit, Free Tetraiodothyronine (FT4) ELISA Kit, TSH ELISA Kit, and Vascular Endothelial Growth Factor (VEGF) ELISA Kit: Shanghai Enzyme Linked Synthetic Agents Association (ELISA). Hematoxylin-Eosin Staining Solution: Yiyuan Biotechnology. Caspase 3 and Bcl-2 Primary Antibodies: Sanying. Secondary Antibody: SeraCare.

[0105] 1.3 Experimental instruments: Multifunctional microplate reader: Biotech, USA; Centrifuge: Hunan Xiangyi; Pathological slide machine: Shanghai Leica.

[0106] 2. Experimental Methods

[0107] 2.1. Modeling Method and Grouping and Administration: PTU is an antithyroid drug that induces goiter by stimulating thyroid cell proliferation. Thirty-four SD rats were selected and, after 7 days of acclimatization, eight were randomly selected as the control group, receiving 1 mL / 100 g of distilled water by gavage daily. The remaining 26 rats were used as the model group, receiving PTU (1 mg / 100 g) by gavage daily for 14 consecutive days.

[0108] Fourteen days later, two rats were randomly selected from both the control group and the model group. Their thyroid glands were harvested for histological observation and weighed, and the thyroid coefficient was calculated. After confirming successful establishment of the thyroid nodule model, the remaining 24 rats in the model group were randomly divided into four groups: the model group, the positive control group (levothyroxine sodium), the low-dose deer antler glue group, and the high-dose deer antler glue group. The control group and the model group were administered distilled water (1 mL / 100 g) daily by gavage. The positive control group (levothyroxine sodium), the low-dose deer antler glue group, and the high-dose deer antler glue group were administered levothyroxine sodium (0.08 μg / g), deer antler glue (2 g / kg), and deer antler glue (4 g / kg), respectively, by gavage. The rats were weighed and their weight recorded every 7 days during the treatment period.

[0109] 2.2. Sample Collection: Twenty-eight days after drug administration, rats were weighed and then anesthetized and euthanized. The abdomen was incised, the abdominal aorta was located, and a syringe was inserted to collect blood from the aorta. The blood was allowed to stand at room temperature for 3 hours, then centrifuged at 3000 rpm for 15 minutes. The supernatant was collected and stored at -80°C. The neck skin was incised to expose the trachea, and the thyroid glands on both sides of the trachea were located. The thyroid tissue was completely separated, and muscles and other tissues were removed. After weighing, the left thyroid tissue was fixed in 4% paraformaldehyde, and the right thyroid tissue was cryopreserved at -80°C.

[0110] 2.3. Evaluation of therapeutic effect:

[0111] 2.3.1. Photographs of rat thyroid tissue and calculation of thyroid coefficient

[0112] Rinse the rat thyroid tissue with physiological saline, dry it with absorbent paper, photograph it, and weigh it. Compare the thyroid tissue weight with the rat's body weight to obtain the thyroid coefficient. Thyroid coefficient = thyroid tissue weight / rat body weight * 100%.

[0113] 2.3.2. Histopathological observation of rat thyroid tissue

[0114] (1) Material collection: Take out the thyroid tissue fixed in 4% paraformaldehyde, trim the thyroid tissue with a blade, and put the trimmed tissue and corresponding label into a dehydration box.

[0115] (2) Dehydration: Place the dehydration box in the basket and place it in the dehydrator for sequential dehydration with alcohol. The dehydration steps are shown in Table 2 below:

[0116] 75% ethanol 4h - 85% ethanol 2h - 90% ethanol 2h - 95% ethanol 1h - anhydrous ethanol I 30min - anhydrous ethanol II 30min - benzene 5-10min - xylene I 5-10min - xylene II 5-10min - wax I 1h - wax II 1h - wax III 1h. Here, I, II, and III indicate the order of the operation steps, all with the same concentration.

[0117] Table 2

[0118] 75% alcohol 4h 85% alcohol 2h 90% alcohol 2h 95% alcohol 1h Anhydrous ethanol I 30min Anhydrous ethanol II 30min Alcohols and benzenes 5-10 min Xylene I 5-10 min Xylene II 5-10 min Wax I 1h Wax II 1h Wax III 1h

[0119] (3) Embedding: The thyroid tissue soaked in wax is embedded in an embedding machine. First, the melted wax is placed into the embedding frame. Before the wax solidifies, the thyroid tissue is taken out from the dehydration box, placed into the embedding frame according to the requirements of the embedding surface, and labeled accordingly. It is cooled on a -20°C freezing stage. After the wax solidifies, the wax block is removed from the embedding frame and trimmed.

[0120] (4) Sectioning: Place the trimmed wax block on a paraffin microtome and section it to a thickness of 4μm. Float the sections on 40℃ warm water in a slide spreader to flatten the thyroid tissue. Use a glass slide to pick up the tissue and place it in a 60℃ oven to bake. After the water has dried and the wax has melted, remove it and store it at room temperature for later use.

[0121] (5) Dewaxing paraffin sections to water: The sections are sequentially immersed in xylene I for 20 min, xylene II for 20 min, anhydrous ethanol I for 10 min, anhydrous ethanol II for 10 min, 95% ethanol for 5 min, 90% ethanol for 5 min, 80% ethanol for 5 min, 70% ethanol for 5 min, and then washed with distilled water. The specific steps are shown in Table 3 below.

[0122] Table 3

[0123]

[0124]

[0125] (6) Hematoxylin staining of cell nuclei: Immerse sections in Harris hematoxylin staining for 5 min, wash with tap water, differentiate with 1% hydrochloric acid alcohol for a few seconds, rinse with tap water, return to blue with 0.6% ammonia solution, and rinse with running water. Eosin staining of cytoplasm: Immerse sections in eosin staining solution for 1-3 min.

[0126] (7) Dehydration and mounting: The slides were placed in 95% ethanol I for 5 min, 95% ethanol II for 5 min, anhydrous ethanol I for 5 min, anhydrous ethanol II for 5 min, xylene I for 5 min, and xylene II for 5 min in sequence to dehydrate and clear the slides. The specific steps are shown in Table 4 below:

[0127] Table 4

[0128] 95% alcohol I 5min 95% alcohol II 5min Anhydrous ethanol I 5min Anhydrous ethanol II 5min Xylene I 5min Xylene II 5min

[0129] Remove the sections from the xylene and let them dry slightly before mounting them with neutral resin.

[0130] (8) Microscopic observation, image acquisition and analysis.

[0131] 2.3.3. Detection of thyroid function in rats

[0132] (1) Serum thyroid function indicators TSH, FT3 and FT4 were measured by ELISA kit. Thyroid tissue frozen at -80℃ was taken out, and the tissue was ground with PBS (at a weight-volume ratio of 1:9) in a cryogenic grinder. After centrifugation at 5000×g for 15 min, the supernatant was collected, and the VEGF content in the thyroid tissue supernatant was detected by ELISA.

[0133] (2) Add sample diluent to the lyophilized standard powder for serial dilution. Remove the antibody-coated microplate strip from the plate frame, add 50 μL of different concentrations of standard or serum to be tested to each well, and immediately add 50 μL of biotinylate antibody to each well. Incubate at 37°C for 1 h.

[0134] (3) After incubation, discard the liquid in the wells and wash the plate three times with washing buffer. Add 80 μL of streptavidin-HRP to each well and incubate at 37°C for 30 min.

[0135] (4) After incubation, discard the liquid in the wells and wash the plate three times with washing buffer. Add 50 μL of substrate A and B to each well and incubate at 37°C in the dark for 10 min.

[0136] (5) After incubation, quickly add 50 μL of stop solution, place it in an ELISA reader, and measure the OD value at 450 nm.

[0137] 2.3.4 Immunohistochemical detection of Caspase3 and Bcl-2 protein expression in rat thyroid tissue

[0138] (1) Dewaxing paraffin sections to water: The thyroid tissue sections were sequentially immersed in xylene I for 15 min, xylene II for 15 min, anhydrous ethanol I for 5 min, anhydrous ethanol II for 5 min, 85% ethanol for 5 min, 75% ethanol for 5 min, and then washed with distilled water. The specific steps are shown in Table 5.

[0139] Table 5

[0140] Xylene I 15min Xylene II 15min Anhydrous ethanol I 5min Anhydrous ethanol II 5min 85% alcohol 5min 75% alcohol 5min Wash with distilled water /

[0141] (2) Antigen retrieval: Tissue slides were placed in a retrieval box filled with citrate antigen retrieval buffer (pH 6.0) and microwaved for antigen retrieval. Microwave on medium heat for 8 minutes, turn off for 8 minutes, then microwave on medium-low for 7 minutes. During this process, excessive evaporation of the buffer should be prevented, and the slides should not be allowed to dry. After natural cooling, the slides were placed in PBS (pH 7.4) and washed three times on a decolorizing shaker for 5 minutes each time.

[0142] (3) Blocking: The slides were placed in 3% hydrogen peroxide solution and incubated at room temperature in the dark for 25 min to block endogenous peroxidase. Then the slides were placed in PBS (pH 7.4) and washed three times on a decolorizing shaker for 5 min each time.

[0143] (4) Draw circles: After slightly drying the slices, draw circles around the tissue with a histochemical pen (to prevent antibodies from flowing away).

[0144] (5) Serum blocking: Add 3% BSA to the circle and incubate at room temperature for 30 min.

[0145] (6) Add primary antibody: Gently shake off the blocking solution, add the primary antibody prepared in PBS at a certain ratio to the slide, and incubate the slide flat in a humidified chamber at 4°C overnight (add a small amount of water to the humidified chamber to prevent antibody evaporation).

[0146] (7) Add secondary antibody: Place the slide in PBS (pH 7.4) and wash it three times on a decolorizing shaker for 5 minutes each time. After slightly drying the slide, add the secondary antibody of the same species as the primary antibody to the circle to cover the tissue, and incubate at room temperature in the dark for 50 minutes.

[0147] (8) DAB staining and counterstaining of cell nuclei: The slides were placed in PBS (pH 7.4) and washed three times on a decolorizing shaker for 5 minutes each time. After the sections were slightly dried, DAB staining agent was added to the circle, and the staining was controlled under a microscope. After complete staining, the slides were rinsed with distilled water or tap water, counterstained with hematoxylin, differentiated with 1% hydrochloric acid alcohol (about 1 second), rinsed with tap water, blued with ammonia, and rinsed with running water.

[0148] (9) Dehydration and mounting: The sections were sequentially immersed in 75% alcohol for 5 min, 85% alcohol for 5 min, anhydrous ethanol I for 5 min, anhydrous ethanol II for 5 min, and xylene I for 5 min to dehydrate and clear the sections. The specific steps are shown in Table 6 below.

[0149] Table 6

[0150]

[0151]

[0152] Remove the sections from the xylene and let them dry slightly before mounting them with neutral resin.

[0153] (10) Cell nuclei stained with hematoxylin appear blue under a white light microscope, while positive expression appears brown or brownish-brown.

[0154] 3. Experimental Results

[0155] 3.1. Effect of deer antler glue small molecule collagen on thyroid coefficient in rats

[0156] On day 7 of modeling, compared with the control group, the weight of rats in other groups was lower. After 14 days of drug administration (day 28 of modeling), the weight of the drug-treated groups increased compared with the modeling groups. Compared with the control group, the thyroid coefficient of the modeling groups was significantly increased. After drug treatment, the thyroid coefficients of the positive control group, the low-dose deer antler glue group, and the high-dose deer antler glue group all decreased significantly. Macroscopically, the thyroid glands in the control group were small and pale pink; the thyroid glands in the modeling group were enlarged and dark red; in the other three drug-treated groups, the color and volume of the thyroid glands recovered to some extent (e.g., ...). Figure 1 (As shown in the figure). This indicates that small molecule collagen from deer antler glue can restore thyroid enlargement caused by PTU, that is, the extracted small molecule collagen from deer antler glue can reduce the thyroid volume and mass of PTU-induced thyroid nodules in rats and reduce the thyroid coefficient.

[0157] 3.2 Effects of small molecule collagen from deer antler glue on pathological changes in rat thyroid tissue

[0158] HE staining results showed that in the blank group, the thyroid tissue follicles were clearly morphological, and the follicular cavities were rich in colloid. In the model group, the follicular cavities were smaller and irregular in shape, most of the follicular cavities disappeared, and a large number of inflammatory cells were infiltrated in the follicular cavities and stroma. In the positive group, the follicular morphology was basically restored, but a small number of inflammatory cell clusters were still accumulated between the follicular cavities and stroma. In the low-dose deer antler gelatin group, the follicular morphology was partially restored, the blood vessels around the follicles were rich, and a large number of inflammatory cells were still accumulated in the follicular cavities and stroma. In the high-dose deer antler gelatin group, most of the follicular cavities were restored, but some follicles still fused and disappeared, and inflammatory cells infiltrating the follicular cavities and stroma were still visible. That is, the small molecule collagen in deer antler gelatin can reduce the thyroid follicles in PTU-induced thyroid nodules in rats, increase the colloid in the follicles, and restore the morphology of thyroid tissue, further indicating that deer antler gelatin can restore the thyroid tissue structure of model rats (e.g., Figure 2 (As shown).

[0159] 3.3 Effects of small molecule collagen from deer antler glue on thyroid function in rats

[0160] TSH, FT3, and FT4 are key indicators of thyroid function, and their levels are significant for the diagnosis of thyroid diseases. TSH is an indicator of thyroid structure and function regulated by the pituitary gland, promoting the synthesis and release of thyroid hormones and thyroid tissue hyperplasia. T3 and T4 are triiodothyronine and tetraiodothyronine, respectively, secreted by the thyroid gland and directly reflecting its function. ELISA results showed that compared with the normal group, the serum TSH level in the model group was significantly increased, while the FT3 and FT4 levels were significantly decreased. Compared with the model group, the drug treatment group showed decreased TSH levels and increased FT3 and FT4 levels. This indicates that small-molecule collagen from deer antler glue can increase the levels of FT3 and FT4 in the serum of PTU-induced thyroid nodules and decrease TSH levels, suggesting that small-molecule collagen from deer antler glue has a preventive and therapeutic effect on thyroid nodules (e.g., Figure 3 (As shown).

[0161] VEGF originates from thyroid follicular endothelial cells and can promote the proliferation and migration of vascular endothelial cells, increase vascular permeability, and participate in the regulation of various physiological and pathological processes. In the development of goiter, VEGF is key to thyroid cell proliferation and angiogenesis. ELISA results showed that VEGF levels in the thyroid tissue of the model group were significantly increased. After 28 days of oral administration of the drug, VEGF levels in the thyroid tissue of the positive group and the high-dose deer antler gelatin group were significantly decreased. Although the VEGF level in the low-dose deer antler gelatin small molecule collagen group was not significantly different from that in the model group, it still showed a decreasing trend. This indicates that deer antler gelatin small molecule collagen can inhibit thyroid cell proliferation by reducing VEGF expression levels in thyroid tissue, thereby regulating nodular goiter (e.g., ...). Figure 4 (As shown).

[0162] 3.4 Effects of small molecule collagen from deer antler glue on apoptosis levels in rat thyroid tissue

[0163] Caspase-3 is a pro-apoptotic gene that can activate apoptosis signaling pathways and induce cell apoptosis, while Bcl-2 is an anti-apoptotic gene that can reduce cell apoptosis by inhibiting the activation of apoptotic proteases. Immunohistochemical results showed that, compared with the control group, the expression level of Caspase-3 in the model group decreased, while the expression level of Bcl-2 increased, inhibiting thyroid cell apoptosis. After drug administration, the expression level of Caspase-3 increased and the expression level of Bcl-2 decreased in the positive group and the low- and high-dose groups of deer antler glue. That is, the small molecule collagen of deer antler glue can upregulate the level of apoptosis in thyroid tissue cells of PTU-induced thyroid nodules in rats (e.g., Figure 5 (As shown).

[0164] In summary, this application found through research that deer antler gelatin small molecule collagen can reduce the thyroid coefficient in rats with thyroid nodules, improve the secretion level of thyroid hormones in rats with thyroid nodules, restore the morphology of thyroid tissue in rats with thyroid nodules, and promote thyroid cell apoptosis; it has a good protective effect on rat models of thyroid nodules.

[0165] The embodiments described above are merely illustrative of several implementation methods of this application, intended to facilitate a detailed understanding of the technical solutions of this application, but should not be construed as limiting the scope of protection of the patent application. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of this application, and these all fall within the scope of protection of this application. Furthermore, it should be understood that after reading the above teachings of this application, those skilled in the art can make various alterations or modifications to this application, and the equivalent forms obtained also fall within the scope of protection of this application. It should also be understood that technical solutions obtained by those skilled in the art based on the technical solutions provided in this application through logical analysis, reasoning, or limited experimentation are all within the scope of protection of the appended claims. Therefore, the scope of protection of this patent application should be determined by the content of the appended claims, and the specification can be used to interpret the content of the claims.

Claims

1. A method for preparing deer antler gelatin small molecule collagen, characterized in that, include: The deer antler disc was mixed with a solvent and then boiled, and the filtrate was collected. The filtrate was concentrated to a thick paste, solidified, and dried to prepare deer antler glue. The deer antler glue was mixed with protease to prepare a mixture, incubated, and the enzymatic supernatant was collected to prepare deer antler glue small molecule collagen. The concentration of the protease is 20 mg / mL to 25 mg / mL.

2. The method for preparing deer antler gelatin small molecule collagen according to claim 1, characterized in that, The preparation method satisfies one or more of the following conditions: (1) The deer flower disc is in powder form; (2) The solvent includes water; and (3) The protease includes proteinase K.

3. The method for preparing deer antler gelatin small molecule collagen according to claim 1, characterized in that, The preparation method satisfies one or more of the following conditions: (1) The mass-to-volume ratio of the deer antler disc to the solvent is 1:(8-12); (2) The decoction process includes repeatedly decocting the residue after decoction 2 to 4 times and combining the filtrates; (3) The concentration process includes heating concentration; optionally, the heating temperature for the concentration process is 50℃-70℃; and (4) The coagulation drying includes natural condensation drying; optionally, the natural condensation drying includes taking it out, cutting it into small pieces and air-drying it.

4. The method for preparing deer antler gelatin small molecule collagen according to claim 1, characterized in that, The preparation method satisfies one or more of the following conditions: (1) The incubation conditions include: a temperature of 55℃-60℃, a pH of 7.5-8.5, and a time of 1.5h-3h; and (2) The method of collecting the enzymatic hydrolysis supernatant includes centrifugation; optionally, the centrifugation parameters include: a rotation speed of 9000 rpm to 10000 rpm and a time of 8 min to 15 min.

5. Deer antler gelatin small molecule collagen prepared by the method according to any one of claims 1 to 4.

6. The use of the deer antler gelatin small molecule collagen as described in claim 5 in the preparation of a drug for treating thyroid diseases.

7. The application according to claim 6, characterized in that, The thyroid diseases mentioned include thyroid nodules.

8. The application according to claim 6, characterized in that, The subjects of the drug were primates; Optionally, the subject of the drug is a human being.

9. A drug for treating thyroid diseases, characterized in that, The pharmaceutical composition comprises the deer antler gelatin small molecule collagen as described in claim 5; Optionally, the drug may also include pharmaceutically acceptable excipients.

10. The medicament according to claim 9, characterized in that, The dosage form of the drug includes one or more of tablets, capsules, granules, oral liquids, and injections.